GH Research is trading 5.16% down at $20.02, with no clear catalyst identified for the October 12 decline.
- The available company announcement disclosed clinical-trial data presentations at the ECNP meeting on October 11, but did not identify negative news or link the presentations to the share-price decline.
- Market context showed only modest index moves, offering no established broader-market explanation.